Kornimate/medical-research-clean huggingface dataset:
study comparing remission rates, in patients with major depressive disorder (mdd)

Conditions: Major Depressive Disorder

Summary: tools known as 'depression scales 'are widely used as assessments to evaluate a patient's response to treatment. the purpose of this study is the evaluation of the remission rates for patients with mdd. the evaluation will involve the use of ham-d 17, and ham-d 7 questionnaires and the comparison of those questionnaires.

12 weeks random

Eligibility criteria:
inclusion criteria: * outpatients * 18-75 years old * patients diagnosed with mdd according to dsm iv without psychotic symptoms * ham-d17 \> or = 18 on inclusion * patients receiving treatment for the first time or changing treatment based on their doctor's decision exclusion criteria: * subjects with potentially problematic compliance * subjects participating in an interventional trial within the last 3 months
evaluation of a supporting transition and resilience to clinical nursing education (strong) study

Conditions: Resilience; Practice Readiness; Depression; Anxiety; Stress; Physical Activity; Eating Behaviours

Summary: this study aims to address the following research questions: 1. evaluate the effectiveness of a supporting transition and resilience to clinical nursing education (strong) program on first year nursing students' anxiety, depression, stress, resilience, practice readiness, physical activity and eating behaviours. 2. explore first year nursing students' experiences and perception of the strong program. participants will be invited to participate in an asynchronous online strong program


Eligibility criteria:
inclusion criteria: * first year nursing students enrolled in the nur1107b nursing practice experience and nur1202c clinical experience i module * above the ages of 18 years * able to comprehend the english language * have a device that can connect to the internet exclusion criteria: * students who refused to participate in this study
assessment of clinical effectiveness and safety of adalimumab and high dose methotrexate in routine clinical practice

Conditions: Rheumatoid Arthritis

Summary: this was a single-arm, multicenter, open label, prospective cohort study (post-marketing observational study) to determine the effectiveness and safety of adalimumab in combination with high-dose methotrexate (≥12 mg/week) in participants with rheumatoid arthritis in a routine clinical setting in japan.

study assessments occurred at baseline, week 12, week 24, week 52, week 76, and week 104. most participants received 40 mg of adalimumab every other week during the study. two participants started at 40 mg of adalimumab every other week, and increased to 80 mg every other week. a few participants had a different dose regimen: 40 mg every three weeks for 3 participants; 40 mg every four weeks for 1 participant; and 40 mg every other week with a switch to 50 mg every three weeks for 4 subjects.

Eligibility criteria:
inclusion criteria: the participants of this study were rheumatoid arthritis (ra) patients for whom adalimumab was prescribed. they must have met the following conditions: * disease duration of ra ≤2 years * methotrexate (mtx) administration ≥3 months prior to starting adalimumab * dose of mtx ≥12mg/week * disease activity score 28 (das28)-c-reactive protein (crp) score \>3.2 exclusion criteria: * participants who had been previously treated with biologics (including tumor necrosis factor \[tnf\] inhibitors and others)

Keywords: rheumatoid arthritis methotrexate
a phase 1 study of brentuximab vedotin given sequentially and combined with multi-agent chemotherapy for cd30-positive mature t-cell and nk-cell neoplasms

Conditions: Lymphoma, Large-Cell, Anaplastic; Lymphoma, NK-cell; Lymphoma, T-cell

Summary: the purpose of this study is to assess the safety profile of brentuximab vedotin sequentially and in combination with multi-agent chemotherapy in front-line treatment for cd30-positive mature t-cell and nk-cell neoplasms, including systemic anaplastic large cell lymphoma. it is a phase 1, open-label, dose escalation study in three arms designed to define the mtd, pk, immunogenicity, and anti-tumor activity of brentuximab vedotin in sequence and in combination with multi-agent front-line chemotherapy.


Eligibility criteria:
inclusion criteria: * treatment-naive cd30-positive mature t-cell and nk-cell neoplasms, including systemic anaplastic large cell lymphoma * measurable disease of at least 1.5 cm * ecog performance status less than or equal to 2 exclusion criteria: * known cerebral/meningeal disease, including history of progressive multifocal leukoencephalopathy * current diagnosis of primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, sezary syndrome or other primary cutaneous lymphomas; extranodal nk/t-cell lymphoma, nasal type * history of another primary malignancy that has not been in remission for at least 3 years * left ventricular ejection fraction \<45% or symptomatic cardiac disease, or myocardial infarction within the past 12 months * viral, bacterial, or fungal infection within two weeks prior to the first dose of brentuximab vedotin * known human immunodeficiency virus (hiv), hepatitis b virus, or hepatitis c virus positive status

Keywords: antibodies, monoclonal antibody-drug conjugate antigens, cd30 drug therapy hematologic diseases lymphoma monomethyl auristatin e lymphoma, large-cell, anaplastic lymphoma, t-cell lymphoma, nk-cell
an observational study on the prediction of adverse events in patients with chronic hepatitis c receiving a long-acting interferon plus ribavirin (guard-c)

Conditions: Hepatitis C, Chronic

Summary: this observational study will assess factors leading to dose reductions/treatment discontinuations and the effect on sustained virological response in patients with chronic hepatitis c receiving a long-acting interferon (e.g. pegasys/peginterferon alfa-2a) and ribavirin. data will be collected from each patient for the duration of their treatment and for up to 6 months thereafter.


Eligibility criteria:
inclusion criteria: * adult patients (according to local legislation) * chronic hepatitis c * treatment with long-acting interferon plus ribavirin * quantifiable hcv rna before initiation of treatment * no contra-indications to long-acting interferon and ribavirin therapy as detailed in the label exclusion criteria: * end stage renal disease * major organ transplantation * concomitant therapy with telbivudine * pregnant or breast-feeding females * male partners of pregnant females
atrioventricular optimization for dual chamber pacemaker

Conditions: AV Block

Summary: this study aims to examine the effect of atrioventricular synchrony in av block patients who received permanent pacemaker. by achieving physiologic ventricular diastolic filling, adjustment of atrioventricular delay of pacemaker might affect the long term outcome of left ventricular function and remodelling. the investigators designed to randomize av block patients who already have or anticipated to receive pacemaker, into two groups. patients in intervention group undergo reprogramming av delay of pacemaker to the best value to increase cardiac output measured by transthoracic echocardiogram and the patients in control group undergo routinely scheduled pacemaker programming. the primary endpoint is improvement of lv systolic function and the secondary endpoint is change in left ventricular volume, cardiac output, bnp, 6-minute walk capacity and nyha class after one year.

it is well-known that persistent right ventricular apical pacing induces left ventricular dysfunction. the most important risk factor is the ratio of ventricular pacing so the effort to reduce pacing ratio is needed. however, almost 100% ventricular pacing is inevitable in complete atrio-ventricular block patients with implanted pacemaker. traditionally the ventricular lead of the pacemaker is positioned in right ventricular apex and previous literatures reported that such right ventricular apical pacing impedes physiological ventricular contraction and induces left ventricular contractile dysfunction in long-term. the alternative positions of ventricular lead are right ventricular outflow tract and ventricular septum but the benefits are not yet clearly prooved. additionally, adjusting atrio-ventricular delay is reportedto affect cardiac output by altering diastolic filling. the investigators aimed to analyze the effect of av dealy in long-term left ventricular contractile function. patients over 19 years old who received or anticipated to receive permanent pacemaker due to av block are randomized to 1:1 ratio into two groups. patients in intervention group undergo reprogramming av delay of pacemaker to the best value to increase cardiac output measured by transthoracic echocardiogram and the patients in control group undergo routinely scheduled pacemaker programming. patients with underlying lv systolic dysfunction or significant valvular heart disease are excluded. six-minute walk test, bnp, transthoracic echocardiogram, nyha class are examined at baseline and after one year.

Eligibility criteria:
inclusion criteria: * received or scheduled to receive permanent pacemaker due to av block exclusion criteria: * left ventricular ejection fraction \ 60mm significant valvular disease (≥mild)
"tunnel" flap vs trapezoidal flap for lateral sinus lift

Conditions: Severe Atrophy of the Edentulous Maxilla

Summary: the goal of this clinical trial is to evaluate the efficacy of the lateral sinus lift procedure using the tunnel technique flap in comparison to the traditional lateral sinus lift in partially or totally edentulous patients with loss of teeth in the maxillary premolar or molar areas and severe alveolar atrophy. the primary questions it aims to answer are: 1. is the tunnel flap technique more suitable for lateral sinus lift than the trapezoidal flap technique in terms of post-operative symptoms? 2. is the tunnel technique safer and more effective than the trapezoidal flap technique in terms of complication rate and the effectiveness of bone grafting? participants will undergo the lateral sinus lift procedure using the tunnel technique, which involves making a vertical anterior incision. patients will receive follow-up care, including phone contact the day after the procedure to detect any issues, and they will keep a diary during the week after surgery to record visual analog scale (vas) pain values and analgesics taken. follow-up surgical visits will be scheduled for suture removal and at 30 days after suture removal. after 6 months, dental implants will be inserted, and prosthetic rehabilitation will take place 6 months later. implants will be monitored for up to 12 months after prosthetic rehabilitation. researchers will compare the outcomes of tunnel flap technique lateral sinus lift with the trapezoidal flap sinus lift.


Eligibility criteria:
inclusion criteria: * edentulous or partly edentulous patients with a unilateral loss of teeth in the maxillary premolar or molar areas * severe alveolar atrophy and a residual severe alveolar ridge height up to 3 mm exclusion criteria: * severe illness * head and neck radiation therapy * chemotherapy * antiresorptive therapy * uncontrolled diabetes * uncontrolled periodontal disease * smoking \>10 cigarettes per day * facial or neck inflammatory or oncologic diseases * obliteration of sinus ostium and osteomeatal complex

Keywords: lateral sinus lift tunnel technique dental implant patient reported outcome measures bone regeneration flap design histology heterologous bone cone beam computed tomography
a multicenter patient registry on outcomes from cryoanalgesia of the intercostal nerves

Conditions: Post Operative Pain

Summary: this is a retrospective and prospective, multicenter, observational patient registry to record outcomes from patients undergoing cryoablation of the intercostal nerves (cryoanalgesia) for post-operative pain management.


Eligibility criteria:
inclusion criteria: 1. patients whose age is 12 years or above, and are able to give informed consent/assent specific to state and national law. 2. patients have been scheduled by physician(s) to undergo or have undergone cryoablation of the intercostal nerves utilizing at least one atricure device or are similar patients treated without the use of cryoablation exclusion criteria: 1. patient is enrolled in a concurrent trial that may impact the treatment offered by the registry devices. 2. patient with exclusion criteria required by local governance. 3. women of childbearing potential who are, or plan to become, pregnant during the time of the study
cardiac anesthesia registry including biosignal database for prognostication of postoperative renal outcome

Conditions: Cardiac Anaesthesia

Summary: aki(acute kidney injury) is a common complication after cardiac surgery which is associated with increased mortality and morbidity. collecting perioperative biosignal data and studying their association with renal outcomes can help improve kidney injury, mortality, and morbidity in cardiac surgical patients. furthermore, the occurrence of aki, length of hospital stay, and recovery of renal function after discharge are closely associated with the development of chronic kidney disease (ckd). therefore, regular monitoring of renal function and related indicators in cardiac surgical patients can help improve long-term outcomes.


Eligibility criteria:
inclusion criteria: * aged 19 years and older scheduled for cardiac surgery using cpb exclusion criteria: * emergency operation, the patient is foreigner or illiterate and unable to read the consent form

Keywords: acute kidney injury cardiovascular surgical procedures cardiopulmonary bypass biomarker biosignal data renal outcome
catheterization during second elective caesarean delivery

Conditions: Wound Infection

Summary: use versus non use of urinary catheterization during second elective caesarean delivery:

evaluation of use versus non use of urinary catheterization during second elective caesarean delivery:by urine analysis 24 hours postoperative to exclude urinary tract infection.

Eligibility criteria:
inclusion criteria * pregnant females who will undergo second elective caesarean section at full term pregnancy (38:41 weeks gestational age). exclusion criteria: * women with history of more than one previous caesarean section. * women with history of a tonic postpartum hemorrhage. * women with urinary tract infection in present pregnancy. * women with diabetes mellitus in present pregnancy. * women with medical disorder in present pregnancy that obligate monitoring of urine output during and after caesarean section, such as severe pre-eclampsia or renal disease with pregnancy. * emergency caesarean section

Keywords: ccswi
group written exposure therapy for posttraumatic stress disorder

Conditions: Posttraumatic Stress Disorder

Summary: the goal of this clinical trial is to test if written exposure therapy (wet) works well in a group setting in patients with post-traumatic stress disorder (ptsd). the main questions it aims to answer are: * does group wet lead to a reduction in symptoms of ptsd? * is group wet better at reducing the number of patients that drop out of treatment in comparison to group cognitive processing therapy (cpt)? participants will: * attend 6 weekly sessions of group wet that will be delivered online by two therapists (psychologist and social worker) * complete questionnaires relating to their symptoms at different points throughout the treatment researchers will evaluate change in ptsd symptoms over time for people who participate in group wet. they will also compare the results of group wet to the results of group cpt to see if group wet shows a similar reduction in symptoms of ptsd and fewer treatment drop-outs.

the primary objective of this study is to evaluate the effectiveness of group wet (g-wet) in reducing symptoms of ptsd in an outpatient hospital setting. in order to do so, we will evaluate outcomes of g-wet from pre- to post-treatment and at one month follow-up. we will also compare outcomes of g-wet to published benchmarks of individual wet outcomes and to a representative cohort of individuals who participate in group cpt at our clinic. a secondary aim of the study is to evaluate attendance and drop-out rates for group wet. in order to achieve this, we will recruit a sample of 63 individuals between the ages of 18 and 65 to participate in a group wet 6-session protocol (1 orientation session and 5 wet sessions) from an outpatient anxiety and related disorders clinic waitlist for group cpt. participants will complete measures assessing ptsd, related symptoms (e.g., depression, anxiety) and group cohesion at pre-treatment, post-treatment, and 1-month follow-up. attendance and drop-out rates will also be recorded. we hypothesize that group wet will be associated with significant reductions in ptsd symptoms and related symptoms and low dropout rates (i.e., less than 10%). we also hypothesize that outcomes for group wet will be comparable to those for group cpt and published individual wet benchmarks.

Eligibility criteria:
inclusion criteria: * between the ages of 18 and older * diagnosis of ptsd * able to provide written informed consent and can read and write in english exclusion criteria: * diagnosis of an active severe substance use disorder (sud) * diagnosis of a psychotic disorder (schizophrenia, schizoaffective disorder, etc.) * untreated active psychotic, manic or hypomanic symptoms * has attempted suicide in the 2 months prior to beginning treatment * has engaged in high-risk self-harm (e.g., cutting, burning, asphyxiation) in the 2 months prior to beginning treatment * has completed cpt in the past * has completed another active ptsd treatment, such as prolonged exposure or emdr within the last year

Keywords: cognitive behavioural therapy written exposure therapy group therapy posttraumatic stress disorder
treatment for aerobic vaginitis by using bofukang vaginal suppository

Conditions: Vaginitis

Summary: aerobic vaginitis was treated by using baofukang suppository 7 days group or baofukang suppository 14 days group.to evaluate the efficacy and safety after treatment.

aerobic vaginitis was treated by using baofukang suppository 7 days group or baofukang suppository 14 days group. group 1: baofukang suppository (1.74g), for vaginal use, 2 capsules per night for 7 days. group 2: baofukang suppository (1.74g), for vaginal use, 2 capsules per night for 14 days. the efficacy and safety will be evaluated 7\~14 days after treatment and 35\~42 days after treatment.

Eligibility criteria:
inclusion criteria: aerobic vaginitis diagnosed based on present ： 1. vaginal dischareg ; 2. ph \> 4.5; 3. donders score≥3; exclusion criteria: 1. patients with other vaginitis, cervical erosion, or suspected gonorrhea, herpes simplex virus infection and other vulvar diseases; 2. patients received systemic or vaginal antifungal or antibiotic treatment within two weeks before admission. 3. pregnancy, lactation and intentional pregnancy; 4. women with liver and kidney dysfunction, low immune function, diabetes, psychosis or other serious diseases; 5. allergic constitution and patients allergic to drug ingredients in this study; 6. those with poor compliance.

Keywords: aerobic vaginitis treatment
impact of physical activity as a coadjuvant treatment in the healing of venous ulcers in primary health care.

Conditions: Varicose Ulcer

Summary: objectives: to evaluate the effectiveness of a structured educational intervention in physical exercise "active legs" as an adjuvant treatment to improve the healing of chronic venous ulcers at 3 months of follow-up, compared with the usual practice in people treated in primary care. secondary objectives: to evaluate if the intervention active legs as an adjuvant treatment produces better results than usual practice in: degree of healing, recurrence, complete healing at 6 months, pain and quality of life. describe degree of adherence and satisfaction with the intervention. design: randomized, multicenter, pragmatic, open clinical trial of parallel groups with 6 months of follow-up. setting: primary care health centers (madrid). subjects: patients with venous ulcers, with treatment in the nursing consultation of the participating centers. sample: 224 participants (112 in each group). intervention: both groups will receive the usual treatment of cleaning, debridement based on humid environment cure and multilayer compression therapy according to the recommendations of community of madrid. the intervention group will also receive the structured educational intervention of lower limbs physical exercise and daily walking patterns. variables: main: complete healing at 3 months follow-up. secondary: degree of healing; ulcer area; quality of life; pain, related to the healing process, prognosis and recurrences; sociodemographic and related adherence and satisfaction. data analysis: main effectiveness: comparison of the incidence of ulcers with complete healing at 3 months of follow-up in both groups, time to complete healing (kaplan-meier and log-rank test). adjustment of prognostic factors (cox regression).


Eligibility criteria:
inclusion criteria: * individuals with a diagnosis of venous ulcers registered in electronic clinical history (history of chronic venous insufficiency and/or venous ulcer) and presence of an ankle brachial index (abi) greater than 0.8 and less than 1.3. * presence at least a venous ulcer of 1cm or more in diameter. if the participant has more than one lesion, the nurse will select the lesion with the highest resvech 2.0 score for the study. * independent ambulation or with the help of devices. * individuals who able to follow the demands of the trial and who provide their written informed consent to participate. exclusion criteria: * patients with mixed ulcers. * acute phase deep vein thrombosis. * patients on treatment with antineoplastic agents. * decompensated heart failure. * rheumatoid arthritis. * acute phase dermatitis, at the time of the study. * patients immobilized at home, institutionalized or displaced residing outside the area where the research is conducted for more than 6 months a year or during the performance of the intervention. * absolute contraindication to perform physical exercise. * patients who are simultaneously participating in another clinical trial.

Keywords: varicose ulcer exercise nurses healthy aging
cognitive-behavioral and physical activity interventions for binge eating and overweight

Conditions: Binge-Eating Disorder; Binge Eating; Overweight and Obesity

Summary: this study aims to perform an open-series pilot trial to examine the efficacy of cognitive-behavioral therapy delivered in a guided self-help format (cbtgsh) with added content related to physical activity (pa), for the treatment of binge-eating disorder (bed), operationalized as bed full diagnostic criteria or bed with the full criteria except for the binge episode size criterion.


Eligibility criteria:
inclusion criteria: 1. 18 to 65 years old; 2. meet dsm-5 criteria for bed or bed but without the size criterion (loc eating); 3. bmi 25-45 kg/m2; 4. sedentary activity pattern (\< 90 mins/week of moderate-to-vigorous intensity recreational physical activity); 5. available for the duration of the treatment and follow-up (7 months); 6. read, comprehend, and write english at a sufficient level to complete study-related materials. exclusion criteria: 1. co-existing psychiatric condition that requires hospitalization or more intensive treatment (e.g., bipolar mood disorders, psychotic illnesses, severe depression). 2. reports active suicidal or homicidal ideation. 3. current anorexia or bulimia nervosa. 4. contraindications to physical activity. 5. blood pressure \>140 systolic or \>90 diastolic. 6. breast-feeding or pregnant, or planning to become pregnant during the study. 7. history of stroke or myocardial infarction. 8. current or recent (within 12 months) drug or alcohol dependence 9. currently receiving effective treatment for eating or weight loss. 10. currently participating in another clinical study.